Effect of Buprenorphine Dose on Treatment Outcome

@article{Fareed2012EffectOB,
  title={Effect of Buprenorphine Dose on Treatment Outcome},
  author={Ayman Fareed and Sreedevi Vayalapalli and Jennifer Casarella and Karen P G Drexler},
  journal={Journal of Addictive Diseases},
  year={2012},
  volume={31},
  pages={18 - 8}
}
The goal of this meta-analysis is to provide evidence based information about proper dosing for buprenorphine maintenance treatment to improve treatment outcome. To be selected for the review and inclusion in the meta-analysis, articles had to be randomized, controlled, or double-blind clinical trials, with buprenorphine as the study drug; the length of buprenorphine maintenance treatment had to be 3 weeks or longer; doses of buprenorphine had to be clearly stated; outcome measures had to… 
Impact of Buprenorphine Dosage on the Occurrence of Relapses in Patients with Opioid Dependence
TLDR
It is confirmed that higher BUP dosages are a protective factor for avoiding relapses in opioid-dependent patients, thus highlighting the importance of adequate BUP dosing in relapse prevention.
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
TLDR
The BUP dose in treatment of OUD should be individualized based on a continuous clinical benefit-risk assessment, as there is currently no consensus regarding optimal dose or dose-range of buprenorphine for treatment of opioid use disorder.
Safety and effectiveness of Buprenorphine-Naloxone sublingual tablet in the treatment of opioid use disorder
TLDR
Detailed evaluations of data from this study indicate a high safety profile, a high effectiveness, tolerance and acceptability with substantial improvements in quality of life, mental and physical health in opioid dependent patients with buprenorphine-naloxone in routine care.
Medication-assisted treatment with buprenorphine: assessing the evidence.
TLDR
Buprenorphine maintenance treatment is associated with improved outcomes compared with placebo for individuals and pregnant women with opioid use disorders and should be considered for inclusion as a covered benefit.
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
AIMS To examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus buprenorphine/naloxone (BUP) treatment for opioid
Predictive factors for relapse in patients on buprenorphine maintenance.
TLDR
Patients with comorbid anxiety disorders, active benzodiazepine use (contrary to clinic policy), or active alcohol abuse, were significantly more likely to relapse and be on a higher buprenorphine maintenance dose.
Analysis of Buprenorphine/Naloxone Dosing Impact on Treatment Duration, Resource Use and Costs in the Treatment of Opioid-Dependent Adults: A Retrospective Study of US Public and Private Health Care Claims
TLDR
Treatment with higher doses of buprenorphine/naloxone was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost.
Buprenorphine treatment for opioid use disorder: recent progress
TLDR
A review of BUP products available for OUD, with a focus on the newer long-acting formulations, finding new BUP formulations were found to be non-inferior to sublingual (SL) BUP and more effective than placebo in reducing opioid use.
Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review
TLDR
Low quality evidence from case reports suggests withdrawal during initiation is common but most often mild in severity, and there is an unmet need for controlled studies to inform their efficacy and safety compared with traditional strategies, including outcomes during initiation and in the long-term.
Buprenorphine dosing choices in specific populations: review of expert opinion
TLDR
An expert group of physicians with experience in addiction care participated in a discussion meeting to share clinical practice experience and develop a consensus on dosing choices, and general agreement that treatment outcomes can be improved by optimising buprenorphine doses in specific subgroups.
...
...

References

SHOWING 1-10 OF 67 REFERENCES
Comparison of Buprenorphine and Methadone in the Treatment of Opioid Dependence
TLDR
Experience of two years substitution treatment in Fribourg suggests that initial induction onto buprenorphine allows for patients to be subgrouped before being given the most appropriate maintenance agent, and further investigation is required into the different dose-related effects of bupenorphine seen in particular subsets of addicts.
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.
TLDR
It is suggested that an adequate dose of buprenorphine will be a useful addition to pharmacotherapy and safety outcome measures provided by clinical monitoring and by analysis of the reported adverse events.
Comparison of buprenorphine and methadone in the treatment of opioid dependence.
TLDR
The results of this study provide further support for the utility of buprenorphine as a new medication in the treatment of opioid dependence and demonstrate efficacy equivalent to that of methadone when used during a clinically guided flexible dosing procedure.
Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.
TLDR
Buprenorphine did not differ from methadone in its ability to suppress heroin use, but retained approximately 10% fewer patients, due possibly to too-slow induction onto buprenorphines.
A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
TLDR
Buprenorphine maintenance at 8 mg/d appears to be less than optimally efficacious under the conditions of the present study, and continued research is needed to reconcile these findings with the more positive results reported by other investigative groups.
Comparison of Buprenorphine and Methadone Maintenance in Opiate Addicts
TLDR
Patients in the buprenorphine group provided a greater proportion of negative urine samples, in particular cocaine-negative samples, compared with the methadone group, although this was not statistically significant, suggesting that this dose may have been too low for those subjects with high levels of dependence.
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
TLDR
Patients in both medication groups showed significant and substantial improvements over time in areas of psychosocial functioning, as assessed by the Addiction Severity Index, rates of urinalysis tests positive for opioids, and self-reports of opioid withdrawal symptoms, illicit opioid use, and cocaine use.
A trial of integrated buprenorphine/naloxone and HIV clinical care.
TLDR
It is concluded that it is feasible to integrate buprenorphine into HIV clinical care for the treatment of opioid dependence and HIV biological markers remained stable or improved during bupenorphine/naloxone treatment.
...
...